特应性皮炎共病的研究进展

doi:10.35541/cjd.20230099

Abstract

Abstract: 【Abstract】 Atopic dermatitis （AD） is a common chronic inflammatory disease that often coexists with atopic diseases such as asthma, allergic rhinitis, and food allergies. In recent years, more and more studies have shown that AD is associated with various diseases such as cardiovascular diseases, autoimmune diseases, and mental disorders, which exacerbate the disease burden on patients with AD and severely affect their quality of life. This review summarizes AD-associated comorbidities reported in previous literature, analyzes their possible common pathogenesis, and explores potential treatments.

Key words: Dermatitis, atopic, Comorbidity, Atopic diseases, Cardiovascular diseases, Autoimmune diseases, Mental illness

Xie Xinran, Zhang Lu, Du Dan, Li Xiaoxue, Li Yanmei, Jiang Xian. Comorbidities in atopic dermatitis[J]. Chinese Journal of Dermatology, 2024, 57(11): 1058-1063.doi:10.35541/cjd.20230099

References ［92］

［1］	Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease［J］. Nat Rev Drug Discov, 2022,21（1）:21⁃40. doi: 10.1038/s41573⁃021⁃00266⁃6.
［2］	Milder E. Atopic dermatitis （generalized neurodermatitis）: the atopic dermatitis⁃asthma⁃hay fever syndrome［J］. Med J Aust, 1958,45（3）:72⁃76.
［3］	Thyssen JP, Halling AS, Schmid⁃Grendelmeier P, et al. Comorbidities of atopic dermatitis⁃what does the evidence say?［J］. J Allergy Clin Immunol, 2023,151（5）:1155⁃1162. doi: 10. 1016/j.jaci.2022.12.002.
［4］	Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis［J］. Nat Rev Dis Primers, 2018,4（1）:1. doi: 10.1038/s41572⁃018⁃0001⁃z.
［5］	Davis D, Drucker AM, Alikhan A, et al. American Academy of Dermatology Guidelines: awareness of comorbidities associated with atopic dermatitis in adults［J］. J Am Acad Dermatol, 2022,86（6）:1335⁃1336.e18. doi: 10.1016/j.jaad.2022.01.009.
［6］	Silverberg JI, Gelfand JM, Margolis DJ, et al. Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults［J］. Ann Allergy Asthma Immunol, 2018,121（5）:604⁃612.e3. doi: 10.1016/j.anai.2018.07.042.
［7］	Knudgaard MH, Andreasen TH, Ravnborg N, et al. Rhinitis prevalence and association with atopic dermatitis: a systematic review and meta⁃analysis［J］. Ann Allergy Asthma Immunol, 2021,127（1）:49⁃56.e1. doi: 10.1016/j.anai.2021.02.026.
［8］	Wu KK, Borba AJ, Deng PH, et al. Association between atopic dermatitis and conjunctivitis in adults: a population⁃based study in the United States［J］. J Dermatolog Treat, 2021,32（4）:455⁃459. doi: 10.1080/09546634.2019.1659480.
［9］	Spergel JM, Blaiss MS, Lio P, et al. Efficacy and safety of crisaborole in patients with mild⁃to⁃moderate atopic dermatitis and other atopic comorbidities［J］. Allergy Asthma Proc, 2021,42（5）:425⁃431. doi: 10.2500/aap.2021.42.210064.
［10］	Narla S, Silverberg JI. Association between atopic dermatitis and autoimmune disorders in US adults and children: a cross⁃sectional study［J］. J Am Acad Dermatol, 2019,80（2）:382⁃389. doi: 10.1016/j.jaad.2018.09.025.
［11］	Roh YS, Huang AH, Sutaria N, et al. Real⁃world comorbidities of atopic dermatitis in the US adult ambulatory population［J］. J Am Acad Dermatol, 2022,86（4）:835⁃845. doi: 10.1016/j.jaad. 2021.11.014.
［12］	Cheng BT, Silverberg NB, Silverberg JI. Association of childhood atopic dermatitis with atopic and nonatopic multimorbidity［J］. Dermatitis, 2021,32（4）:214⁃219. doi: 10.1097/DER.0000000 000000644.
［13］	Wang LC, Chiang BL. Early⁃onset⁃early⁃resolving atopic dermatitis does not increase the risk of development of allergic diseases at 3 years old［J］. J Formos Med Assoc, 2020,119（12）:1854⁃1861. doi: 10.1016/j.jfma.2020.02.014.
［14］	Kok WL, Yew YW, Thng TG. Comorbidities associated with severity of atopic dermatitis in young adult males: a national cohort study［J］. Acta Derm Venereol, 2019,99（7）:652⁃656. doi: 10.2340/00015555⁃3175.
［15］	Bulger DA, Minhas S, Asbeutah AA, et al. Chronic systemic inflammatory skin disease as a risk factor for cardiovascular disease［J］. Curr Probl Cardiol, 2021,46（5）:100799. doi: 10. 1016/j.cpcardiol.2021.100799.
［16］	Jung HJ, Lee DH, Park MY, et al. Cardiovascular comorbidities of atopic dermatitis: using National Health Insurance data in Korea［J］. Allergy Asthma Clin Immunol, 2021,17（1）:94. doi: 10.1186/s13223⁃021⁃00590⁃x.
［17］	Ascott A, Mulick A, Yu AM, et al. Atopic eczema and major cardiovascular outcomes: a systematic review and meta⁃analysis of population⁃based studies［J］. J Allergy Clin Immunol, 2019,143（5）:1821⁃1829. doi: 10.1016/j.jaci.2018.11.030.
［18］	Silverwood RJ, Forbes HJ, Abuabara K, et al. Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study［J］. BMJ, 2018,361:k1786. doi: 10.1136/bmj.k1786.
［19］	He H, Li R, Choi S, et al. Increased cardiovascular and atherosclerosis markers in blood of older patients with atopic dermatitis［J］. Ann Allergy Asthma Immunol, 2020,124（1）:70⁃78. doi: 10.1016/j.anai.2019.10.013.
［20］	Hedderson MM, Asgari MM, Xu F, et al. Rates of cardiovascular events among patients with moderate⁃to⁃severe atopic dermatitis in an integrated health care system: a retrospective cohort study［J］. PLoS One, 2022,17（11）:e0277469. doi: 10.1371/journal.pone.0277469.
［21］	Pandher K, Ghamrawi RI, Heron CE, et al. Controversial cardiovascular and hematologic comorbidities in atopic dermatitis［J］. Arch Dermatol Res, 2022,314（4）:317⁃324. doi: 10.1007/s00403⁃021⁃02240⁃z.
［22］	Appiah MM, Haft MA, Kleinman E, et al. Atopic dermatitis: review of comorbidities and therapeutics［J］. Ann Allergy Asthma Immunol, 2022,129（2）:142⁃149. doi: 10.1016/j.anai.2022.05.015.
［23］	Rhee TM, Choi EK, Han KD, et al. Impact of the combinations of allergic diseases on myocardial infarction and mortality［J］. J Allergy Clin Immunol Pract, 2021,9（2）:872⁃880.e4. doi: 10. 1016/j.jaip.2020.09.008.
［24］	Villani AP, Pavel AB, Wu J, et al. Vascular inflammation in moderate⁃to⁃severe atopic dermatitis is associated with enhanced Th2 response［J］. Allergy, 2021,76（10）:3107⁃3121. doi: 10. 1111/all.14859.
［25］	He H, Del Duca E, Diaz A, et al. Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities［J］. J Allergy Clin Immunol, 2021,147（4）:1369⁃1380. doi: 10.1016/j.jaci.2020.08.041.
［26］	Qi H, Wang L, Li L. Association between atopic dermatitis and major cardiovascular outcomes: a two⁃sample Mendelian randomization study［J］. Dermatol Pract Concept, 2022,12（4）:e2022165. doi: 10.5826/dpc.1204a165.
［27］	De Bruyn Carlier T, Badloe F, Ring J, et al. Autoreactive T cells and their role in atopic dermatitis［J］. J Autoimmun, 2021,120:102634. doi: 10.1016/j.jaut.2021.102634.
［28］	Holmes J, Fairclough LC, Todd I. Atopic dermatitis and autoimmunity: the occurrence of autoantibodies and their association with disease severity［J］. Arch Dermatol Res, 2019,311（3）:141⁃162. doi: 10.1007/s00403⁃019⁃01890⁃4.
［29］	Wu PC, Wu CY, Lyu YS, et al. Association between bullous pemphigoid and atopic dermatitis: a population⁃based case⁃control study in Taiwan［J］. Arch Dermatol Res, 2023,315（3）:419⁃427. doi: 10.1007/s00403⁃022⁃02372⁃w.
［30］	de Lusignan S, Alexander H, Broderick C, et al. Atopic dermatitis and risk of autoimmune conditions: population⁃based cohort study［J］. J Allergy Clin Immunol, 2022,150（3）:709⁃713. doi: 10.1016/j.jaci.2022.03.030.
［31］	Ivert LU, Wahlgren CF, Lindelöf B, et al. Association between atopic dermatitis and autoimmune diseases: a population⁃based case⁃control study［J］. Br J Dermatol, 2021,185（2）:335⁃342. doi: 10.1111/bjd.19624.
［32］	Attah Johnson FY, Mostaghimi H. Co⁃morbidity between dermatologic diseases and psychiatric disorders in Papua New Guinea［J］. Int J Dermatol, 1995,34（4）:244⁃248. doi: 10.1111/j.1365⁃4362.1995.tb01589.x.
［33］	Holmes A, Marella P, Rodriguez C, et al. Alexithymia and cutaneous disease morbidity: a systematic review［J］. Dermatology, 2022,238（6）:1120⁃1129. doi: 10.1159/000524736.
［34］	Ramirez FD, Chen S, Langan SM, et al. Association of atopic dermatitis with sleep quality in children［J］. JAMA Pediatr, 2019,173（5）:e190025. doi: 10.1001/jamapediatrics.2019.0025.
［35］	Chang YS, Chiang BL. Sleep disorders and atopic dermatitis: a 2⁃way street?［J］. J Allergy Clin Immunol, 2018,142（4）:1033⁃1040. doi: 10.1016/j.jaci.2018.08.005.
［36］	Sandhu JK, Wu KK, Bui TL, et al. Association between atopic dermatitis and suicidality: a systematic review and meta⁃analysis［J］. JAMA Dermatol, 2019,155（2）:178⁃187. doi: 10.1001/jamadermatol.2018.4566.
［37］	Pan TL, Bai YM, Cheng CM, et al. Atopic dermatitis and dementia risk: a nationwide longitudinal study［J］. Ann Allergy Asthma Immunol, 2021,127（2）:200⁃205. doi: 10.1016/j.anai. 2021.03.001.
［38］	Pandher K, Patel K, Wang JV, et al. The other side of atopic dermatitis: an evaluation of psychosocial comorbidities［J］. Clin Dermatol, 2021,39（2）:296⁃298. doi: 10.1016/j.clindermatol. 2020.07.002.
［39］	Patel KR, Immaneni S, Singam V, et al. Association between atopic dermatitis, depression, and suicidal ideation: a systematic review and meta⁃analysis［J］. J Am Acad Dermatol, 2019,80（2）:402⁃410. doi: 10.1016/j.jaad.2018.08.063.
［40］	Qi HJ, Li LF. Association of atopic dermatitis with depression and suicide: a two⁃sample Mendelian randomization study［J］. Biomed Res Int, 2022,2022:4084121. doi: 10.1155/2022/4084121.
［41］	Ascott A, Mansfield KE, Schonmann Y, et al. Atopic eczema and obesity: a population⁃based study［J］. Br J Dermatol, 2021,184（5）:871⁃879. doi: 10.1111/bjd.19597.
［42］	Huang AH, Roh YS, Sutaria N, et al. Real⁃world comorbidities of atopic dermatitis in the pediatric ambulatory population in the United States［J］. J Am Acad Dermatol, 2021,85（4）:893⁃900. doi: 10.1016/j.jaad.2021.03.016.
［43］	Shalom G, Dreiher J, Kridin K, et al. Atopic dermatitis and the metabolic syndrome: a cross⁃sectional study of 116 816 patients［J］. J Eur Acad Dermatol Venereol, 2019,33（9）:1762⁃1767. doi: 10.1111/jdv.15642.
［44］	Ali Z, Ulrik CS, Agner T, et al. Association between atopic dermatitis and the metabolic syndrome: a systematic review［J］. Dermatology, 2018,234（3⁃4）:79⁃85. doi: 10.1159/000491593.
［45］	Iturriaga C, Bustos MF, Le Roy C, et al. Association between obesity and atopic dermatitis in children: a case⁃control study in a high obesity prevalence population［J］. Pediatr Dermatol, 2023,40（1）:64⁃68. doi: 10.1111/pde.15110.
［46］	Matthewman J, Mansfield KE, Prieto⁃Alhambra D, et al. Atopic eczema⁃associated fracture risk and oral corticosteroids: a population⁃based cohort study［J］. J Allergy Clin Immunol Pract, 2022,10（1）:257⁃266.e8. doi: 10.1016/j.jaip.2021.09.026.
［47］	Mukovozov IM, Morra DE, Giustini D, et al. Atopic dermatitis and bone health: a systematic review［J］. J Eur Acad Dermatol Venereol, 2021,35（3）:615⁃628. doi: 10.1111/jdv.16895.
［48］	Lin TL, Wu CY, Yen JJ, et al. Fracture risks in patients with atopic dermatitis: a nationwide matched cohort study［J］. Ann Allergy Asthma Immunol, 2021,127（6）:667⁃673.e2. doi: 10. 1016/j.anai.2021.09.004.
［49］	Wu D, Wu XD, Zhou X, et al. Bone mineral density, osteopenia, osteoporosis, and fracture risk in patients with atopic dermatitis: a systematic review and meta⁃analysis［J］. Ann Transl Med, 2021,9（1）:40. doi: 10.21037/atm⁃20⁃4708.
［50］	Lowe KE, Mansfield KE, Delmestri A, et al. Atopic eczema and fracture risk in adults: a population⁃based cohort study［J］. J Allergy Clin Immunol, 2020,145（2）:563⁃571.e8. doi: 10.1016/j.jaci.2019.09.015.
［51］	Droitcourt C, Vittrup I, Kerbrat S, et al. Risk of systemic infections in adults with atopic dermatitis: a nationwide cohort study［J］. J Am Acad Dermatol, 2021,84（2）:290⁃299. doi: 10. 1016/j.jaad.2020.07.111.
［52］	Ren Z, Silverberg JI. Association of atopic dermatitis with bacterial, fungal, viral, and sexually transmitted skin infections［J］. Dermatitis, 2020,31（2）:157⁃164. doi: 10.1097/DER.0000 000000000526.
［53］	Han JH, Yoon JW, Yook HJ, et al. Evaluation of atopic dermatitis and cutaneous infectious disorders using sequential pattern mining: a nationwide population⁃based cohort study［J］. J Clin Med, 2022,11（12）:3422. doi: 10.3390/jcm11123422.
［54］	Serrano L, Patel KR, Silverberg JI. Association between atopic dermatitis and extracutaneous bacterial and mycobacterial infections: a systematic review and meta⁃analysis［J］. J Am Acad Dermatol, 2019,80（4）:904⁃912. doi: 10.1016/j.jaad.2018.11.028.
［55］	Choi CW, Yang BR, Suh DI, et al. Infection, antibiotic exposure and development of atopic dermatitis: a nationwide case⁃control study［J］. J Dermatol, 2020,47（7）:707⁃713. doi: 10.1111/1346⁃8138.15387.
［56］	Blicharz L, Usarek P, Młynarczyk G, et al. Nasal colonization by Staphylococci and severity of atopic dermatitis［J］. Dermatitis, 2020,31（3）:215⁃222. doi: 10.1097/DER.0000000000000568.
［57］	Mansfield KE, Schmidt S, Darvalics B, et al. Association between atopic eczema and cancer in England and Denmark［J］. JAMA Dermatol, 2020,156（10）:1086⁃1097. doi: 10.1001/jamadermatol.2020.1948.
［58］	Zhu Y, Wang H, He J, et al. Atopic dermatitis and skin cancer risk: a systematic review［J］. Dermatol Ther （Heidelb）, 2022,12（5）:1167⁃1179. doi: 10.1007/s13555⁃022⁃00720⁃2.
［59］	Wang L, Bierbrier R, Drucker AM, et al. Noncutaneous and cutaneous cancer risk in patients with atopic dermatitis: a systematic review and meta⁃analysis［J］. JAMA Dermatol, 2020,156（2）:158⁃171. doi: 10.1001/jamadermatol.2019.3786.
［60］	Cho JM, Davis D, Wetter DA, et al. Association between atopic dermatitis and squamous cell carcinoma: a case⁃control study［J］. Int J Dermatol, 2018,57（3）:313⁃316. doi: 10.1111/ijd. 13857.
［61］	Chou WY, Lai PY, Hu JM, et al. Association between atopic dermatitis and colorectal cancer risk: a nationwide cohort study［J］. Medicine （Baltimore）, 2020,99（1）:e18530. doi: 10.1097/MD.0000000000018530.
［62］	Rafiq M, Hayward A, Warren⁃Gash C, et al. Allergic disease, corticosteroid use, and risk of Hodgkin lymphoma: a United Kingdom nationwide case⁃control study［J］. J Allergy Clin Immunol, 2020,145（3）:868⁃876. doi: 10.1016/j.jaci.2019.10.033.
［63］	Hui⁃Beckman JW, Goleva E, Berdyshev E, et al. Endotypes of atopic dermatitis and food allergy［J］. J Allergy Clin Immunol, 2023,151（1）:26⁃28. doi: 10.1016/j.jaci.2022.07.021.
［64］	Rittiphairoj T, Charoenngam N, Ponvilawan B, et al. Atopic dermatitis is a risk factor for rheumatoid arthritis: a systematic review and meta⁃analysis［J］. Dermatitis, 2021,32（1S）:S15⁃S23. doi: 10.1097/DER.0000000000000781.
［65］	Pavel AB, Zhou L, Diaz A, et al. The proteomic skin profile of moderate⁃to⁃severe atopic dermatitis patients shows an inflammatory signature［J］. J Am Acad Dermatol, 2020,82（3）:690⁃699. doi: 10.1016/j.jaad.2019.10.039.
［66］	Leung D, Calatroni A, Zaramela LS, et al. The nonlesional skin surface distinguishes atopic dermatitis with food allergy as a unique endotype［J］. Sci Transl Med, 2019,11（480）:eaav2685. doi: 10.1126/scitranslmed.aav2685.
［67］	Basu MN, Mortz CG, Jensen TK, et al. Biomarkers in asthma in the context of atopic dermatitis in young children［J］. Pediatr Allergy Immunol, 2022,33（7）:e13823. doi: 10.1111/pai.13823.
［68］	Andersen Y, Egeberg A, Skov L, et al. Comorbidities of atopic dermatitis: beyond rhinitis and asthma［J］. Curr Dermatol Rep, 2017,6（1）:35⁃41. doi: 10.1007/s13671⁃017⁃0168⁃7.
［69］	Fölster⁃Holst R. The role of the skin microbiome in atopic dermatitis⁃correlations and consequences［J］. J Dtsch Dermatol Ges, 2022,20（5）:571⁃577. doi: 10.1111/ddg.14709.
［70］	Keller J, Gomez R, Williams G, et al. HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cognition［J］. Mol Psychiatry, 2017,22（4）:527⁃536. doi: 10.1038/mp.2016.120.
［71］	Sirufo MM, De Pietro F, Bassino EM, et al. Osteoporosis in skin diseases［J］. Int J Mol Sci, 2020,21（13）:4749. doi: 10.3390/ijms 21134749.
［72］	Eichenfield LF, Bieber T, Beck LA, et al. Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis［J］. Am J Clin Dermatol, 2019,20（3）:443⁃456. doi: 10.1007/s40257⁃019⁃00445⁃7.
［73］	Simpson EL, Bieber T, Guttman⁃Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis［J］. N Engl J Med, 2016,375（24）:2335⁃2348. doi: 10.1056/NEJMoa 1610020.
［74］	Cork MJ, Eckert L, Simpson EL, et al. Dupilumab improves patient⁃reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health⁃related quality of life in moderate⁃to⁃severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2［J］. J Dermatolog Treat, 2020,31（6）:606⁃614. doi: 10.1080/095466 34.2019.1612836.
［75］	Boguniewicz M, Beck LA, Sher L, et al. Dupilumab improves asthma and sinonasal outcomes in adults with moderate to severe atopic dermatitis［J］. J Allergy Clin Immunol Pract, 2021,9（3）:1212⁃1223.e6. doi: 10.1016/j.jaip.2020.12.059.
［76］	Spergel BL, Ruffner MA, Godwin BC, et al. Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use［J］. Ann Allergy Asthma Immunol, 2022,128（5）:589⁃593. doi: 10.1016/j.anai.2022.01.019.
［77］	Nettis E, Patella V, Lombardo C, et al. Efficacy of dupilumab in atopic comorbidities associated with moderate⁃to⁃severe adult atopic dermatitis［J］. Allergy, 2020,75（10）:2653⁃2661. doi: 10.1111/all.14338.
［78］	McInnes IB, Anderson JK, Magrey M, et al. Trial of upadacitinib and adalimumab for psoriatic arthritis［J］. N Engl J Med, 2021,384（13）:1227⁃1239. doi: 10.1056/NEJMoa2022516.
［79］	Rubbert⁃Roth A, Enejosa J, Pangan AL, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis［J］. N Engl J Med, 2020,383（16）:1511⁃1521. doi: 10.1056/NEJMoa2008250.
［80］	Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phaseⅢ, double⁃blind, randomized controlled trial［J］. Arthritis Rheumatol, 2019,71（11）:1788⁃1800. doi: 10.1002/art.41032.
［81］	van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis （SELECT⁃AXIS 1）: a multicentre, randomised, double⁃blind, placebo⁃controlled, phase 2/3 trial［J］. Lancet, 2019,394（10214）:2108⁃2117. doi: 10.1016/S0140⁃6736（19）32534⁃6.
［82］	van der Heijde D, Baraliakos X, Sieper J, et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double⁃blind, randomised, placebo⁃controlled phase 3 trial［J］. Ann Rheum Dis, 2022,81（11）:1515⁃1523. doi: 10.1136/ard⁃2022⁃222608.
［83］	Hasni SA, Gupta S, Davis M, et al. Phase 1 double⁃blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus［J］. Nat Commun, 2021,12（1）:3391. doi: 10.1038/s41467⁃021⁃23361⁃z.
［84］	Sandborn WJ, Ghosh S, Panes J, et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis［J］. Gastroenterology, 2020,158（8）:2139⁃2149.e14. doi: 10.1053/j.gastro.2020.02.030.
［85］	Sandborn WJ, Feagan BG, Loftus EV Jr, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn's disease［J］. Gastroenterology, 2020,158（8）:2123⁃2138.e8. doi: 10.1053/j.gastro.2020.01.047.
［86］	冯佩英. 生物制剂治疗特应性皮炎和特应性共病的研究进展［J］. 中山大学学报（医学科学版）, 2022,43（1）:1⁃9. doi: 10. 13471/j.cnki.j.sun.yat⁃sen.univ（med.sci）.2022.0101.
［87］	Silverberg JI. Selected comorbidities of atopic dermatitis: atopy, neuropsychiatric, and musculoskeletal disorders［J］. Clin Dermatol, 2017,35（4）:360⁃366. doi: 10.1016/j.clindermatol.2017.03.008.
［88］	Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease［J］. Ann Intern Med, 2004,141（10）:764⁃770. doi: 10.7326/0003⁃4819⁃141⁃10⁃200411160⁃00007.
［89］	Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease［J］. J Allergy Clin Immunol, 2016,137（1）:19⁃27. doi: 10.1016/j.jaci.2015.10.023.
［90］	Silverberg JI, de Bruin⁃Weller M, Bieber T, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results［J］. J Allergy Clin Immunol, 2022,149（3）:977⁃987.e14. doi: 10.1016/j.jaci.2021.07.036.
［91］	Guttman⁃Yassky E, Thyssen JP, Silverberg JI, et al. Safety of upadacitinib in moderate⁃to⁃severe atopic dermatitis: an integrated analysis of phase 3 studies［J］. J Allergy Clin Immunol, 2023,151（1）:172⁃181. doi: 10.1016/j.jaci.2022.09.023.
［92］	Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate⁃to⁃severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseⅢ trials［J］. Br J Dermatol, 2020,183（2）:242⁃255. doi: 10.1111/bjd.18898.

[1]	Tian Jing, Deng Sisi, Song Zhiqiang . A comparison of clinical characteristics between atopic and non-atopic prurigo nodularis [J]. Chinese Journal of Dermatology, 2024, 57(4): 331-337.
[2]	Guo Lei, Cao Chunyan, Fang Xiaoya, Feng Suying. Analysis of current status and risk factors of multidrug-resistant bacteria wound infections in patients with autoimmune bullous diseases [J]. Chinese Journal of Dermatology, 2024, 57(2): 155-160.
[3]	Jing Ke, Wang Yuan, Li Suo, Feng Suying. Autoimmune subepidermal bullous diseases characterized by annular erythema and blisters: a retrospective analysis of 25 cases [J]. Chinese Journal of Dermatology, 2023, 56(9): 832-838.
[4]	Su Chang, Sui Xiuli, Liu Ruiling, Cao Yiqun, Jiang Hong, Yan Cairong, Wang Huiping, Qi Yuqing. Omalizumab for the treatment of 74 patients with chronic spontaneous urticaria accompanied by other allergic diseases: a clinical analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 512-517.
[5]	Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on treat-to-target approach for the treatment of psoriasis with biological agents [J]. Chinese Journal of Dermatology, 2023, 56(3): 191-203.
[6]	Wang Qi, Jian Zhe. Three-dimensional culture techniques of mesenchymal stem cells and their application in the treatment of skin diseases [J]. Chinese Journal of Dermatology, 2023, 0(2): 20230083-e20230083.
[7]	Yang Qi, Zheng Jie. Effect of biologics on cardiovascular comorbidities of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(2): 165-169.
[8]	Li Xiuzhen, Xu Xiulian. Effects of interleukin-23 inhibitors on psoriasis comorbidities [J]. Chinese Journal of Dermatology, 2023, 0(2): 20210809-e20210809.
[9]	Zhang Ying, Zhang Chunlei, Wang Wenhui, Zhang Hua, Wang Xiaoyu, Zhou Xin, Guo Jinzhu. Comparative analysis of metabolic indicators in patients with persistent and non-persistent psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(12): 1131-1137.
[10]	Zhu Xinyu, Pan Xiaoyuan, Yang Haijing, Wang Fei, Dong Zhengbang. Clinical features of coronavirus disease 2019 in patients with autoimmune blistering diseases [J]. Chinese Journal of Dermatology, 2023, 56(11): 1023-1027.
[11]	Li Baizhang, Kang Pan, Zhang Xiaoying, Zhu Guannan, Li Shuli, Li Chunying. Construction and validation of a risk prediction model for diabetes mellitus in patients with vitiligo [J]. Chinese Journal of Dermatology, 2022, 55(7): 576-582.
[12]	Committee on Autoimmune Diseases, China Dermatologist Association. Cyclosporine in the treatment of immune-related skin diseases: an expert proposal [J]. Chinese Journal of Dermatology, 2022, 55(6): 471-479.
[13]	Shan Ying, Zuo Yagang. Correlation between autoimmune bullous diseases and psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(5): 452-455.
[14]	Tian Jing, Liang Yuan, Shen Chunping, Zhao Mutong, Wang Yang, Wang Shan, Jiao Lei, Ma Lin. Analysis of short-term efficacy and safety of the first subcutaneous injection of dupilumab in the treatment of moderate-to-severe childhood atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 299-303.
[15]	Zhao Ying, Wang Juanjuan, Ji Jiang, Su Wenxing, Wei Yuqian, Leng Hong, Ding Yujie, Shi Xin. Interleukin-17A-mediated psoriasis and cardiovascular comorbidities [J]. Chinese Journal of Dermatology, 2022, 55(1): 76-79.

Comorbidities in atopic dermatitis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［92］

Related Articles 15

Metrics

Comments

Recommended 10